A
Andrea Bezjak
Researcher at Princess Margaret Cancer Centre
Publications - 293
Citations - 20806
Andrea Bezjak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Lung cancer & Radiation therapy. The author has an hindex of 62, co-authored 277 publications receiving 19027 citations. Previous affiliations of Andrea Bezjak include Ontario Institute for Cancer Research & University Health Network.
Papers
More filters
Journal ArticleDOI
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
Corinne Faivre-Finn,Michael Snee,Linda Ashcroft,W. Appel,Fabrice Barlesi,Adityanarayan Bhatnagar,Andrea Bezjak,Felipe Cardenal,Pierre Fournel,Susan Harden,Cécile Le Péchoux,Rhona McMenemin,Nazia Mohammed,Mary O'Brien,Jason Pantarotto,Veerle Surmont,Jan P. van Meerbeeck,Penella J. Woll,Paul Lorigan,Fiona H Blackhall +19 more
TL;DR: Survival outcomes did not differ between twice-daily and once-daily concurrent chemoradiotherapy in patients with limited-stage small-cell lung cancer, and toxicity was similar and lower than expected with both regimens.
Journal ArticleDOI
Cone-beam computed tomography for on-line image guidance of lung stereotactic radiotherapy: localization, verification, and intrafraction tumor position.
Thomas G. Purdie,Jean-Pierre Bissonnette,Kevin Franks,Andrea Bezjak,David Payne,F. Sie,Michael B. Sharpe,David A. Jaffray +7 more
TL;DR: In-room volumetric imaging, such as CBCT, is essential for target localization accuracy in lung stereotactic body radiotherapy and imaging that relies on bony anatomy as a surrogate of the target may provide erroneous results in both localization and verification.
Journal ArticleDOI
Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Andrea Bezjak,Dongsheng Tu,Lesley Seymour,Gary M. Clark,Aleksandra Trajkovic,Mauro Zukin,Joseph Ayoub,Sergio Lago,Ronaldo A. Ribeiro,Alexandra Gerogianni,Arnold Cyjon,Jonathan Noble,Francis Laberge,Raymond T. T. Chan,David Fenton,Joachim von Pawel,Martin Reck,Frances A. Shepherd +17 more
TL;DR: Eerrlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL.
Journal ArticleDOI
Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus.
Feng-Ming Spring Kong,Timothy Ritter,Douglas J. Quint,Suresh Senan,Laurie E. Gaspar,R.U. Komaki,Coen W. Hurkmans,Robert Timmerman,Andrea Bezjak,Jeffrey D. Bradley,Benjamin Movsas,Lon H. Marsh,Paul Okunieff,Hak Choy,Walter J. Curran +14 more
TL;DR: The dose limits and standardize the three-dimenional (3D) radiographic definition for the organs at risk (OARs) for thoracic radiotherapy (RT), including the lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus are reviewed.
Journal ArticleDOI
Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.
Andrea Bezjak,Rebecca Paulus,Laurie E. Gaspar,Robert Timmerman,William L. Straube,William F. Ryan,Yolanda I. Garces,Anthony T. Pu,Anurag K. Singh,Gregory M.M. Videtic,Ronald C. McGarry,Puneeth Iyengar,Jason Pantarotto,James J. Urbanic,Alexander Y. Sun,Megan E. Daly,Inga S. Grills,Paul W. Sperduto,Daniel P. Normolle,Jeffrey D. Bradley,Hak Choy +20 more
TL;DR: Outcomes in this medically inoperable group of mostly elderly patients with comorbidities were comparable with that of patients with peripheral early-stage tumors, and the MTD for this study was 12.0 Gy/fx; it was associated with 7.2% DLTs and high rates of tumor control.